{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:35:56Z","timestamp":1769855756490,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,6]]},"DOI":"10.7759\/cureus.38630","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T14:33:28Z","timestamp":1683383608000},"source":"Crossref","is-referenced-by-count":3,"title":["Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Abu baker","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moiz I","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He L","year":"2022","unstructured":"He L, Wang J, Ping F, et al.. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022, 182:513-9. 10.1001\/jamainternmed.2022.0338","journal-title":"JAMA Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim W","year":"2008","unstructured":"Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008, 60:470-512. 10.1124\/pr.108.000604","journal-title":"Pharmacol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/life13041012","article-title":"A comprehensive review on weight loss associated with anti-diabetic medications","volume":"13","author":"Haddad F","year":"2023","unstructured":"Haddad F, Dokmak G, Bader M, Karaman R. A comprehensive review on weight loss associated with anti-diabetic medications. Life (Basel). 2023, 13:10.3390\/life13041012","journal-title":"Life (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01268-2","article-title":"Study design and baseline characteristics of patients with T2DM in the post-marketing safety study of dulaglutide in China (trust-CHN)","volume":"13","author":"Guo L","year":"2022","unstructured":"Guo L, Li L, Yu Q, Wang N, Chen J, Wang Z, Ding Y. Study design and baseline characteristics of patients with T2DM in the post-marketing safety study of dulaglutide in China (trust-CHN). Diabetes Ther. 2022, 13:1231-44. 10.1007\/s13300-022-01268-2","journal-title":"Diabetes Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck M","year":"2014","unstructured":"Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014, 37:2149-58. 10.2337\/dc13-2761","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle J","year":"2016","unstructured":"Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016, 32:776-90. 10.1002\/dmrr.2810","journal-title":"Diabetes Metab Res Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac150.808","article-title":"Psun241 a case of dulaglutide-induced acute pancreatitis in a diabetic patient-a case report","volume":"6","author":"Abdelmasih R","year":"2022","unstructured":"Abdelmasih R, Saeed Z, Ashraf B, Abdelmaseih R, Nasser H. Psun241 a case of dulaglutide-induced acute pancreatitis in a diabetic patient-a case report. J Endocr Soc. 2022, 6:A388-9. 10.1210\/jendso\/bvac150.808","journal-title":"J Endocr Soc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20938","article-title":"Case report of acute pancreatitis associated with combination treatment of dulaglutide and glipizide","volume":"14","author":"Babajide O","year":"2022","unstructured":"Babajide O, K C N, Solaimanzadeh I, Shiferaw-Deribe Z. Case report of acute pancreatitis associated with combination treatment of dulaglutide and glipizide. Cureus. 2022, 14:e20938. 10.7759\/cureus.20938","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2017.22.1.15","article-title":"Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes","volume":"22","author":"Lee S","year":"2017","unstructured":"Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017, 22:15-26. 10.6065\/apem.2017.22.1.15","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff M","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011, 141:150-6. 10.1053\/j.gastro.2011.02.018","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio LL","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132:2131-57. 10.1053\/j.gastro.2007.03.054","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino F","year":"2015","unstructured":"Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015, 38:2241-9. 10.2337\/dc14-1625","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0984","article-title":"Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide","volume":"40","author":"Nauck MA","year":"2017","unstructured":"Nauck MA, Frossard JL, Barkin JS, Anglin G, Hensley IE, Harper KD, Milicevic Z. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017, 40:647-54. 10.2337\/dc16-0984","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li L","year":"2014","unstructured":"Li L, Shen J, Bala MM, et al.. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014, 348:g2366. 10.1136\/bmj.g2366","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/116202-dulaglutide-trulicity-induced-acute-pancreatitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:01Z","timestamp":1707508681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/116202-dulaglutide-trulicity-induced-acute-pancreatitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.38630","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,6]]}}}